Department of Gynecological Oncology, Oslo University Hospital, Oslo, Norway
Faculty of Medicine, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
Int J Gynecol Cancer. 2023 Aug 7;33(8):1279-1286. doi: 10.1136/ijgc-2023-004355.
This prospective cohort study evaluated the introduction of an enhanced recovery after surgery (ERAS) pathway in a tertiary gynecologic oncology referral center. Compliance and clinical outcomes were studied in two separate surgical cohorts.
Patients undergoing laparotomy for suspected or verified advanced ovarian cancer at Oslo University Hospital were prospectively included in a pre- and post-implementation cohort. A priori, patients were stratified into: cohort 1, patients planned for surgery of advanced disease; and cohort 2, patients undergoing surgery for suspicious pelvic tumor. Baseline characteristics, adherence to the pathway, and clinical outcomes were assessed.
Of the 439 included patients, 235 (54%) underwent surgery for advanced ovarian cancer in cohort 1 and 204 (46%) in cohort 2. In cohort 1, 53% of the patients underwent surgery with an intermediate/high Aletti complexity score. Post-ERAS, median fasting times for solids (13.1 hours post-ERAS vs 16.0 hours pre-ERAS, p<0.001) and fluids (3.7 hours post-ERAS vs 11.0 hours pre-ERAS, p<0.001) were significantly reduced. Peri-operative fluid management varied less and was reduced from median 15.8 mL/kg/hour (IQR 10.8-22.5) to 11.5 mL/kg/hour (IQR 9.0-15.4) (p<0.001). In cohort 2 only there was a statistically significant reduction in length of stay (mean (SD) 4.3±1.5 post-ERAS vs 4.6±1.2 pre-ERAS, p=0.026). Despite stable readmission rates, there were significantly more serious complications reported in cohort 1 post-ERAS.
ERAS increased adherence to current standards in peri-operative management with significant reduction in fasting times for both solids and fluids, and peri-operative fluid administration. Length of stay was reduced in patients with suspicious pelvic tumor. Despite serious complications being common in patients with advanced disease undergoing debulking surgery, a causal relationship with the ERAS protocol could not be established. Implementing ERAS and continuous performance auditing are crucial to advancing peri-operative care of patients with ovarian cancer.
本前瞻性队列研究评估了在一家三级妇科肿瘤转诊中心引入术后加速康复(ERAS)方案的效果。在两个单独的手术队列中研究了依从性和临床结局。
前瞻性纳入在奥斯陆大学医院因疑似或确诊晚期卵巢癌而行剖腹手术的患者,进入实施前和实施后队列。根据预设标准,患者被分为:队列 1,计划接受高级别疾病手术的患者;队列 2,因可疑盆腔肿瘤而行手术的患者。评估基线特征、对方案的依从性和临床结局。
在纳入的 439 例患者中,235 例(54%)在队列 1中因晚期卵巢癌行手术,204 例(46%)在队列 2中因可疑盆腔肿瘤行手术。在队列 1 中,53%的患者接受了具有中等/高 Aletti 复杂性评分的手术。实施 ERAS 后,固体食物(ERAS 后 13.1 小时 vs ERAS 前 16.0 小时,p<0.001)和液体(ERAS 后 3.7 小时 vs ERAS 前 11.0 小时,p<0.001)的禁食时间显著缩短。围手术期液体管理变化减少,从中位数 15.8 mL/kg/h(IQR 10.8-22.5)降至 11.5 mL/kg/h(IQR 9.0-15.4)(p<0.001)。仅在队列 2中,住院时间有统计学显著缩短(ERAS 后 4.3±1.5 天 vs ERAS 前 4.6±1.2 天,p=0.026)。尽管再入院率稳定,但队列 1 中报告的严重并发症明显更多。
ERAS 增加了围手术期管理的现行标准的依从性,显著缩短了固体和液体的禁食时间,以及围手术期液体的使用。在因可疑盆腔肿瘤而行手术的患者中,住院时间缩短。尽管在接受减瘤手术的晚期疾病患者中,严重并发症很常见,但与 ERAS 方案之间的因果关系无法建立。实施 ERAS 和持续的绩效审计对于提高卵巢癌患者的围手术期护理至关重要。